Challenges in HIV Management: Enhancing the Quality of Life for Elderly PLWH, Policy Interventions are Imperative

Challenges in HIV Management: Enhancing the Quality of Life for Elderly PLWH, Policy Interventions are Imperative

2023.10.12
From July 23-26, 2023, the 12th International AIDS Society HIV Science Conference (IAS 2023) was held in Brisbane, Australia. In recent years, with the continuous advancement of modern antiretroviral therapy (ART), the life expectancy of people living with HIV (PLWH) has significantly improved. However, the accompanying aging issue of PLWH is becoming increasingly prominent, posing unprecedented challenges to HIV management. The quality of life and living conditions of elderly PLWH have become hot topics of discussion at this conference.
SGBCC 2023 Expert Voting: Surgical Treatment

SGBCC 2023 Expert Voting: Surgical Treatment

2023.10.12
The 18th St. Gallen International Breast Cancer Conference (SGBCC 2023) took place in Vienna, the "City of Music," from March 15th to 18th, 2023. SGBCC gathered breast cancer opinion leaders from around the world to discuss and vote on the latest and most controversial topics in early breast cancer diagnosis and treatment, culminating in the biennial St. Gallen International Expert Consensus on Early Breast Cancer. On the final day of the conference, the expert voting session took center stage. Oncology Frontier has  compiled  the following summary of the expert votes on surgical treatment.
2023 SGBCC Expert Voting: Early Treatment Decisions for Triple-Negative Breast Cancer

2023 SGBCC Expert Voting: Early Treatment Decisions for Triple-Negative Breast Cancer

2023.10.12
The 18th St. Gallen International Breast Cancer Conference (SGBCC 2023) was held in Vienna, the "City of Music," from March 15 to 18, 2023. SGBCC brought together breast cancer opinion leaders from around the world to discuss and vote on the most cutting-edge and controversial topics in the diagnosis and treatment of early-stage breast cancer. This resulted in the updated St. Gallen International Expert Consensus on Early Breast Cancer every two years.
SGBCC International Dialogue | Dr. JianZhang  Discusses with Dr. Harbeck: Is Chemotherapy Necessary for ER+/HER2- Breast Cancer Patients with Low Genetic Risk but High Clinical Risk?

SGBCC International Dialogue | Dr. JianZhang  Discusses with Dr. Harbeck: Is Chemotherapy Necessary for ER+/HER2- Breast Cancer Patients with Low Genetic Risk but High Clinical Risk?

2023.10.12
The 18th St. Gallen International Breast Cancer Conference (SG-BCC 2023) was held in Vienna, the "City of Music," from March 15 to 18, 2023. Breast cancer experts from around the world gathered at this conference to discuss the most cutting-edge and controversial topics in the diagnosis and treatment of early-stage breast cancer, leading to the formation of the updated St. Gallen International Expert Consensus on Early Breast Cancer every two years. Oncology Frontier invited Dr. Jian Zhang from Fudan University Affiliated Cancer Hospital to have an in-depth discussion with Dr. Nadia Harbeck from the University of Munich on the topic of whether chemotherapy is needed for patients with low genetic risk but high clinical risk (ER+/HER2-) breast cancer.
SGBCC 2023 | Academician  BingheXu: Breast Cancer Treatment and Research – An Asian Perspective

SGBCC 2023 | Academician  BingheXu: Breast Cancer Treatment and Research – An Asian Perspective

2023.10.12
The 18th St.Gallen International Breast Cancer Conference (SG-BCC 2023) was held in Vienna, the "City of Music," from March 15 to 18, 2023. Academician Binghe Xu  from the Cancer Hospital of the Chinese Academy of Medical Sciences delivered a presentation titled "Breast Cancer Treatment and Research - An Asian Perspective" during the "Session 10: Global Perspective on Breast Cancer Treatment." After his presentation, Academician Binghe Xu  had an interview with Oncology Frontier to discuss related content.
SGBCC  International Dialogue|Dr. LiZhu & Dr. Giuseppe Curigliano Discuss the Need for Adjuvant Therapy After Achieving pCR in Neoadjuvant Treatment

SGBCC  International Dialogue|Dr. LiZhu & Dr. Giuseppe Curigliano Discuss the Need for Adjuvant Therapy After Achieving pCR in Neoadjuvant Treatment

2023.10.12
Neoadjuvant therapy has become an integral part of breast cancer treatment, with its increasing application in clinical practice. However, improving the effectiveness of neoadjuvant therapy and optimizing subsequent treatment strategies is a complex issue to consider. At the 18th St.Gallen Breast Cancer Conference (SGBCC 2023), a debate titled "If you achieve pCR after neoadjuvant, do you need adjuvant therapy?" drew global expert attention. Oncology Frontier had  invited Dr. Li Zhu from Shanghai Jiao Tong University School of Medicine, First People's Hospital, and Dr. Giuseppe Curigliano from the University of Milan School of Medicine to engage in an in-depth discussion on this topic.
SGBCC International Dialogue | Dr.Jia Wang & Dr.William Gradishar: Controversies in Surgical Treatment for Stage IV Breast Cancer Patients at Initial Diagnosis

SGBCC International Dialogue | Dr.Jia Wang & Dr.William Gradishar: Controversies in Surgical Treatment for Stage IV Breast Cancer Patients at Initial Diagnosis

2023.10.12
There is currently a lack of consensus on whether surgical treatment should be performed for patients with stage IV breast cancer at the initial diagnosis. At the 18th St.Gallen Breast Cancer Conference (SGBCC 2023), a debate titled "Surgery of the primary for stage IV disease" garnered global expert attention.